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Abstract
Background: Glioblastoma multiforme is a highly aggressive brain tumor with a poor prognosis, and advances in
treatment have led to only marginal increases in overall survival. We and others have shown previously that the
therapeutic ketogenic diet (KD) prolongs survival in mouse models of glioma, explained by both direct tumor
growth inhibition and suppression of pro-inflammatory microenvironment conditions. The aim of this study is to
assess the effects of the KD on the glioma reactive immune response.
Methods: The GL261-Luc2 intracranial mouse model of glioma was used to investigate the effects of the KD on the
tumor-specific immune response. Tumor-infiltrating CD8+ T cells, CD4+ T cells and natural killer (NK) cells were
analyzed by flow cytometry. The expression of immune inhibitory receptors cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) and programmed death 1 (PD-1) on CD8+ T cells were also analyzed by flow cytometry. Analysis
of intracellular cytokine production was used to determine production of IFN, IL-2 and IFN- in tumor-infiltrating
CD8+ T and natural killer (NK) cells and IL-10 production by T regulatory cells.
Results: We demonstrate that mice fed the KD had increased tumor-reactive innate and adaptive immune
responses, including increased cytokine production and cytolysis via tumor-reactive CD8+ T cells. Additionally, we
saw that mice maintained on the KD had increased CD4 infiltration, while T regulatory cell numbers stayed
consistent. Lastly, mice fed the KD had a significant reduction in immune inhibitory receptor expression as well as
decreased inhibitory ligand expression on glioma cells.
Conclusions: The KD may work in part as an immune adjuvant, boosting tumor-reactive immune responses in the
microenvironment by alleviating immune suppression. This evidence suggests that the KD increases tumor-reactive
immune responses, and may have implications in combinational treatment approaches.
Keywords: Glioblastoma, Glioma, Ketogenic diet, Metabolism, Immunosuppression, Microenvironment, Immune
inhibitory checkpoints, Immunology, CTLA-4, PD-1
Background
Glioblastoma multiforme (GBM) is a highly aggressive,
heterogeneous brain tumor with poor prognosis [1].
Standard of care includes surgical resection followed by
radiation and chemotherapy, however median survival is
about 15 months with a two-year survival of 30 % and a
5-year survival of <5 % in adults [2]. Despite break-
throughs in our understanding of the disease, thera-
peutic options available for GBM have remained largely
unchanged over the past three decades. This has led to
only marginal increases in overall patient survival and
new therapeutic approaches to enhance brain tumor
treatment are warranted.
One novel therapeutic approach for GBM involves tar-
geting a phenotypic trait shared by virtually all cancer
cells, deregulated metabolism. It has been postulated
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that metabolic alteration such as that seen with the thera-
peutic ketogenic diet (KD) may be an effective anti-cancer
strategy [3]. The KD is a high fat, low-carbohydrate/
adequate protein nutritional therapy used in the treatment
of refractory epilepsy [4]. We and others have shown that
the KD enhances survival in mouse models of malignant
glioma [5–8]. We also demonstrated that the KD greatly
enhanced survival when administered in combination with
radiation [6]. Mechanistically, the KD alters a variety of
processes that influence the tumor microenvironment in-
cluding hypoxia, inflammation, angiogenesis and vascular
permeability [5, 9]. However, the effect of a KD on the
GBM tumor-reactive immune response has yet to be
examined.
We have recently shown that an unrestricted KD de-
creases expression of the hypoxia marker carbonic anhy-
drase IX (CAIX) and the key mediator of the hypoxic
response hypoxia-inducible factor alpha (HIF-1α) in a
mouse model of malignant glioma [9]. Wei et al. demon-
strated that hypoxia leads to inhibition of T cell prolifer-
ation and effector responses, with induction of CD4 +
FoxP3+ T regulatory cells in GBM [10]. This study also
demonstrated that this immunosuppressive effect could
be reversed by inhibiting HIF-1α. As tumor hypoxia is
linked to the less favorable Th2 immune response [11],
it is possible that by altering the hypoxic response the
KD may promote a Th1 type tumor-reactive immune re-
sponse. Additionally, we previously demonstrated that
the KD reduces activation of the pro-inflammatory tran-
scription factor, nuclear factor kappa B (NF-κB) and re-
duces expression of cyclooxygenase-2 (COX-2) [5, 9],
both of which have been implicated in hypoxia-driven
immunosuppression [12]. Taken together these studies
led us to hypothesize that the KD may alter the tumor
microenvironment to alleviate immune suppression and
enhance anti-tumor immunity.
In this paper we investigated the role that an unre-
stricted KD plays in alleviating tumor immune suppres-
sion in a mouse model of malignant glioma. We studied
the direct effects of this metabolic therapy on total infil-
tration and function of tumor-reactive T cells and nat-
ural killer (NK) cells, as well as the indirect benefits of
this metabolic therapy on alleviation of immune sup-
pression in the tumor microenvironment.
Methods
Antibodies and cell lines
Fluorochrome-conjugated anti-mouse monoclonal anti-
bodies (Abs) specific for CD8α, CD274, CD279, CTLA-
4, CD86, tumor necrosis factor (TNF), interferon gamma
(IFNγ), interleukin-2 (IL-2), CD4, FoxP3, NKp46, CD3,
and interleukin-10 (IL-10) were purchased from eBios-
ciences (San Diego, CA) and diluted 1:200 prior to use.
Anti-CD8 depletion antibodies were purified from the
mouse 2.43 hybridoma cell line purchased from ATCC
(Manassas, VA). Bioluminescent GL261-Luc 2 cells were
derived and grown as previously described [6].
Mice and tumor implantation
GL261-Luc2 cells were harvested by trypsinization,
washed and resuspended at a concentration of 1–2x107
cells/ml in DMEM without FCS and implanted into ten
week old B6 (Cg)-Tyrc-23/J (albino C57BL/6) mice (The
Jackson Laboratory, Bar Harbor, ME) at an average
weight of 19–20 g as previously described [5, 6, 13].
Briefly, animals were anesthetized by an intraperitoneal
injection of ketamine (10 mg/kg) and xylazine (80 mg/kg),
placed in a stereotactic apparatus and an incision was
made over the cranial midline. A burrhole was made
0.1 mm posterior to the bregma and 2.3 mm to the right
of the midline. A needle was inserted to a depth of 3 mm
and withdrawn 0.4 mm to a depth of 2.6 mm. Two μl of
GL261-luc2 cells (107 cells/ml) were infused over the
course of 3 min. The burrhole was closed with bonewax
and the incision was sutured.
Treatment and animal monitoring
Following implantation surgery, animals were fed stand-
ard rodent chow for 3 days. Animals were then random-
ized to remain on standard diet (SD) or changed to a
KD (KetoCal®; Nutricia North America, Gaithersburg,
MD). The KD was obtained directly from the manufac-
turer and is a nutritionally complete diet providing a 4:1
ratio of fats to carbohydrates plus protein (72 % fat,
15 % protein, and 3 % carbohydrate). The KD was pre-
pared by mixing KetoCal® with water (2:1) and fed to the
animals each day (ad libitum). Bioluminescence was an-
alyzed to quantify tumor burden as described [6]. Serum
β-hydroxybutyrate (βHB) and glucose levels were mea-
sured using a Precision Xtra® blood monitoring system
(Abbott Laboratories, Abbott Park, IL). Animals were
weighed every 3–5 days and euthanized upon occur-
rence of visible symptoms of impending death such as
hunched posture, reduced mobility and weight loss
[5, 14]. Measurements of animal body weight, blood
βHB, and glucose can be found in (Additional file 1:
Figure S1).
CD8 depletion in vivo
Supernatant from 2.43 hybridoma cells was precipitated in
saturated ammonium sulfate to 45 % (v/v) overnight
at 4 °C and dialyzed against PBS for 24 h. The concentra-
tion of dialyzed antibody was determined by UV spectros-
copy, and 0.3 mg of purified antibody was administered
via intraperitoneal injection twice before tumor inocula-
tion (day −5 and −3), and continued every three days after
inoculation until euthanasia. CD8 T cell depletion was
confirmed by flow cytometry analysis of peripheral blood
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mononuclear cells, as previously described [15]. Confirm-
ation of CD8 depletion can be found in (Additional file 2:
Figure S2).
Tissue preparation
When mice became symptomatic they were anesthetized
with 80 mg/kg ketamine, 10 mg/kg xylazine followed by
cardiac perfusion with ice-cold RPMI media just prior to
euthanization. Tumor tissue and non-tumor contralat-
eral brain were collected in RPMI media and run
through a 70 μm filter. Tumor-infiltrating cells were iso-
lated from tumor tissue by centrifugation over a 30/70 %
Percoll gradient (Sigma-Aldrich, St. Louis, MO) before
antibody staining and analysis of cell populations on an
LSRFortessa flow cytometer (BD Biosciences, San Jose,
CA). Flow cytometry data were analyzed with FlowJo8.8
(Tree Star Inc., Ashland, OR) and graphs were generated
using Prism 5 software (GraphPad Software, La Jolla,
CA). Gating strategies and isotype controls can be found
in the Additional file 3: Figure S3 and Additional file 4:
Figure S4 section.
Intracellular cytokine staining
Lymphocytes were cultured alone or stimulated with
GL261-Luc2 cells at a density of 106 cells per well (6-
well plate). GolgiStop (BD Biosciences) was added at 1 h
to inhibit export of cytokines and after a further 5 h of
incubation, cells were stained for extracellular proteins.
Permeabilization and intracellular staining for cytokines
was done according to manufacturer’s instructions using
the Cytofix/Cytoperm kit (BD Biosciences). Gating strat-
egies and isotype controls can be found in the Additional
file 5: Figure S5 and Additional file 6: Figure S6 section.
Cytotoxicity ELISA
Lymphocytes were isolated from tumor tissue, and cul-
tured alone or with GL261-Luc2 cells at varying effector
to target cell ratios. Lactate dehydrogenase (LDH) ELISA
was performed using CytoTox 96 Non-Radioactive Cyto-
toxicity Assay (Promega, Madison, WI). Absorbance was
recorded at 490 nm.
Animals and virus
Six to 8-week-old female C57BL/6 mice were obtained
from The Jackson Laboratory. All experiments were
conducted under Arizona State University IACUC ap-
proval and followed all relevant federal guidelines and
institutional policies. The Armstrong and clone 13
strains of Lymphocytic Choriomeningitis Virus (LCMV)
were grown as previously described [16]. Mice were in-
fected with 2 x 105 PFU of LCMV (Armstrong) injected
intraperitoneally or 2 x 106 PFU of LCMV (clone 13)
injected intravenously.
Statistical methods
Statistical analyses were performed using GraphPad
Prism 5 (GraphPad Software, San Diego, CA). All values
are represented as the mean ± SD and significance was
determined using both the Student’s t test and the Mann
Whitney non-parametric test. P < 0.05 was considered
statistically significant. For the Kaplan Meier survival
data the log-rank (Mantel-Cox) test was used to assess
statistical significance.
Results
KD enhanced survival is mediated by CD8+ T cells
Tumor bearing animals maintained on the ketogenic diet
(KD) had a greater median survival when compared to
animals fed a standard diet (SD) (Fig. 1a). In order to
effectively evaluate the importance of tumor-reactive
CD8+ T cells in slowing tumor progression, CD8+ T cells
were depleted from immune competent albino C57BL/6
mice bearing tumors. There was a significant decrease in
survival of mice depleted of CD8+ T cells prior to tumor
cell inoculation in comparison to wild type mice main-
tained on SD (Fig. 1b). In order to determine the import-
ance of CD8+ T cells in the anti-tumor effects of the KD,
CD8+ T cell depleted animals were treated with the KD
and survival was measured. Although the KD significantly
improved survival in immune intact mice when compared
to those maintained on SD, that difference in survival is
lost when CD8+ T cells are depleted and mice are treated
with the KD in comparison to immune intact mice fed SD
(Fig. 1c). Furthermore, the KD significantly increased sur-
vival in immune intact mice when compared to CD8 de-
pleted mice fed KD (Fig. 1d). Analysis of bioluminescence
data also shows slower tumor growth in animals treated
with KD when compared to SD in both immune compe-
tent and CD8 depleted mice (Fig. 1e).
The KD enhances immune cell infiltration, and increases
the ratio of tumor-reactive CD4+ T cells to Treg ratio
To evaluate the effects of the KD on immune cell infil-
tration into the tumor, amounts of tumor-infiltrating
CD8+, CD4+, CD4 + FoxP3+, and NKp46 + CD3- cells
were tested. There was no significant difference in the
percentage of tumor-infiltrating CD8+ T cells between
mice fed the KD and the SD (Fig. 2a). However, mice fed
the KD had a significant increase in the percentage of
CD4+ T cells infiltrating the tumor in comparison to SD
(Fig. 2b). This increase in the percentage of CD4+ T cells
was not due to an increase in the percentage of FoxP3 +
CD4+ T regulatory (Treg) cells (Fig. 2c), and therefore
the ratio of CD4+ T cells to Treg cells is significantly in-
creased in tumors from mice fed a KD (Fig. 2e). In com-
parison, the CD8+ T cell to Treg cell ratio remained
unchanged when comparing the two treatment groups
(Fig. 2d). Lastly, there was no difference in the
Lussier et al. BMC Cancer  (2016) 16:310 Page 3 of 10
percentage of tumor-infiltrating NK cells in tumors from
mice fed a KD compared to SD (Fig. 2f ). Similar results
were found when looking at the total number of infil-
trating cells (data not shown). Therefore, the KD en-
hances CD4+ T cell presence at the tumor site, and this
increase is not associated with an increase in the T regu-
latory cell subset.
The KD influences expression of immune inhibitory
receptors on tumor-infiltrating lymphocytes, and immune
inhibitory ligands on glioma cells
Tumor cell expression of immune inhibitory checkpoint
proteins is a major mechanism by which tumors limit the
efficacy of immune responses in vivo. To examine the in-
fluence of the KD on immune inhibitory checkpoints we
evaluated changes of immune inhibitory receptor expres-
sion on CD8+ tumor-infiltrating lymphocytes (TILs), and
changes in expression of inhibitory ligands on the tumor
cells. Mice fed the KD had significantly reduced expres-
sion of two inhibitory ligands, PD-1 (Fig. 3a) and CTLA-4
on CD8+ TILs (Fig. 3b). Additionally, mice fed the KD
had reduced expression of CD86 (Fig. 3c) and PD-L1
(Fig. 3d) on the tumor cells. This suggests that the KD
may alter tumor-mediated T cell suppression by reducing
the number of cells that are susceptible to inhibition
through the PD-1 and CTLA-4 inhibitory pathways.
The KD enhances innate and adaptive tumor specific
immune function against glioma cells
To evaluate the influence of the KD on tumor-reactive
immune cells at the tumor site, immune cell function
from TILs removed from the tumor site at time of nec-
ropsy was tested. Intracellular cytokine staining follow-
ing stimulation with tumor cells showed that when
compared to SD, the KD significantly increases the abil-
ity of tumor-reactive CD8+ T cells to produce interferon
gamma (IFNγ), tumor necrosis factor (TNF), and inter-
leukin 2 (IL-2) when stimulated with GL261-Luc2 cells
(Fig. 4a). Additionally, the KD significantly increased
cytotoxic capabilities of tumor-reactive T cells from mice
Fig. 1 Enhanced survival with the ketogenic diet is mediated in part by CD8 T cells. Kaplan-Meier survival curves for ketogenic diet (KD) versus
standard diet (SD) (a), SD versus SD + CD8 depletion (b), SD versus KD + CD8 depletion (c), KD versus KD + CD8 depletion (d). Bioluminescent
tumor signals plotted as in vivo photon count versus days post-implantation (e). N = 12 for immune competent mice; N = 5 for CD8 depleted
mice; Log-rank (Mantel-Cox) test; p-values indicated on graphs
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Fig. 2 CD4+ T cell infiltration increases in mice fed the KD, without increases in Treg cell numbers. Flow cytometry analysis was performed to
assess the cell types infiltrating tumors from mice fed both SD and KD. CD8 T cells (a), CD4 T cells (b) and CD4 + FoxP3+ T regulatory cells (c)
were assessed. The ratio of CD8 T cells to T regulatory cells (d) and CD4 to T regulatory cells (e) were determined. The percent of infiltrating
NKp46 + CD3- natural killer cells (f) were also assessed. N = 5; student’s two-tailed t-test; ***p < 0.001; ****p < 0.0001
Fig. 3 The ketogenic diet reduces expression of immune inhibitory receptors and ligands expressed in glioma tumors. Expression of the immune
inhibitory receptors, PD-1 (a) and CTLA-4 (b) on infiltrating CD8 T cells isolated from tumors from mice fed each diet were assessed. Expression of
the immune inhibitory ligands, CD86 (c) and PD-L1 (d), on GL261-Luc2 tumor tissue was also assessed. N = 5; student’s two tailed t-test; *p < 0.05;
**p < 0.01; ****p < 0.0001
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when compared to SD (Fig. 4b). The function of T regu-
latory cells was also assessed by intracellular cytokine
staining for interleukin 10 (IL-10). Although we did not
find a difference in the number of tumor-infiltrating
Tregs, those found in the tumors from animals fed the
KD produced significantly less IL-10 in response to
GL261-Luc2 cells when compared to animals maintained
on SD (Fig. 4c). Lastly, we studied natural killer (NK)
cell function and found that tumor-infiltrating NK cells
from mice fed the KD produce significantly more IFNγ
and TNF in response to GL261-Luc2 cells than the cells
isolated from SD fed animals (Fig. 4d). Whether through
direct interaction with immune cells, or through allevi-
ation of tumor immune suppression in the microenvir-
onment, the KD significantly enhances tumor-reactive
immune function.
The KD enhances innate and adaptive tumor-reactive
immune responses indirectly via alleviation of immune
suppression
To determine if the KD specifically enhances TIL func-
tion in the tumor microenvironment or alters global im-
mune status, the effects of the KD on immune responses
to two strains of Lymphocytic Choriomeningitis Virus
(LCMV) was examined. Non-tumor bearing mice were
infected with either LCMV Armstrong or Clone 13, and
CD8 T cell function was accessed at Day 6 and 30. There
was no significant difference in cytokine production by
CD8+ T cells responding to either LCMV dominant epi-
topes, GP33 or NP396 (Fig. 5a) at either time point or
with either infection regardless of diet. Additionally,
there was no significant difference in the percentage of
PD-1 + CD8+ T cells between KD and SD fed mice
Fig. 4 The ketogenic diet significantly enhances tumor-reactive CD8+ T cell and NK cell activity. Tumor-infiltrating lymphocytes (TILs) isolated
from gliomas from mice fed KD versus SD were cultured alone (white bar) or in the presence of GL261-Luc2 tumor cells (black bar) to access
activity. Analysis of IFNγ, TNF and IL-2 production in tumor-infiltrating CD8+ T cells was performed (a). Cytotoxic capability of CD8+ T cells isolated
from tumors was assessed following exposure to GL261-Luc2 cells (b). IL-10-production in CD4 + FoxP3+ T regulatory cells was also assessed in
response to stimulation with GL261-Luc2 cells (c). IFNγ and TNF production in the infiltrating NKp46 + CD3- natural killer cells isolated from tumors
were assessed (d). N = 5; student’s two-tailed t-test between the antigen-challenged SD and KD groups only; *p < 0.05; **p < 0.01; ***p < 0.001
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(Fig. 5b). Although the KD did not alter CD8 function
against acute and chronic viral infections, it did alter im-
mune mediated killing at the tumor site suggesting alle-
viation of immune suppression is specific to the tumor
microenvironment.
Discussion
Activated effector immune responses against glioblast-
oma multiforme (GBM) may provide benefits in patient
survival; however these tumors exert a variety of im-
munosuppressive pressures on the surrounding micro-
environment [17, 18]. These include increased induction
of CD8 + FOXp3+ regulatory T cells (Tregs), elevated
immunosuppressive cytokine levels, diminished CD4+
helper T cell populations, tolerized antigen presenting
cells and upregulated immune inhibitory checkpoints
[19]. For example, Tregs suppress immune responses by
secreting cytokines such as IL-10 and facilitating inacti-
vation of CD8+ cytotoxic T cells by direct cell-to-cell in-
teractions [20]. A key observation in immunosuppressed
GBM patients is a decrease in CD4+ T cells with an in-
creased proportion of Tregs and increased IL-10 levels
[19, 21]. The current study demonstrated that tumors
from animals maintained on the KD had a significantly
increased CD4+ T cell population and a decreased pro-
portion of Tregs when compared to control animals.
Further the Tregs isolated from animals maintained on
the KD produced significantly less IL-10 when stimu-
lated with tumor cells. Similar results were demon-
strated in a study using a pancreatic cancer model which
showed increased CD4+ T cells and decreased Tregs
when animals were fed a KD [22].
In addition to increasing Tregs and IL-10 production
in the microenvironment, tumors exploit immune in-
hibitory signaling pathways involving direct cell-to-cell
interactions. Key mediators of this system include cyto-
toxic T-lymphocyte-associated protein 4 (CTLA-4) and
programmed death-1 (PD-1) which are found on the
surface of activated effector T cells and act as check-
points to regulate immune proliferation and activation.
Fig. 5 The ketogenic diet had no effect on T cell activity in an acute and chronic mouse model of LCMV infection. Splenocytes from non-tumor
bearing mice infected with LCMV Armstrong or Clone 13 were isolated at day 6 and 30, and stimulated with GP33 or NP396 antigens. IFNγ + TNF +
CD8+ cells in mice fed SD versus KD (a). PD-1 + CD8+ expression in mice fed SD versus KD (b). N = 5 in each group
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For example, when PD-1 binds its ligand, programmed
death ligand 1 (PD-L1), activated CD8+ and CD4+ T
cells are suppressed [23]. Increased PD-L1 expression
has been observed on tumor cells and immune cells
within the GBM microenvironment [24–27] and leads to
direct inactivation of CD8+ T cells [28, 29]. The current
study demonstrates significantly decreased expression of
PD-1 and CTLA-4 on tumor-infiltrating CD8+ T cells
and decreased expression of their ligands (PD-L1 and
CD86, respectively) on dissociated tumor cells from ani-
mals maintained on the KD when compared to control
animals. Blockade of the CTLA-4 and PD1 immune
checkpoints represents a potentially important anti-
glioma strategy that has proven effective in preclinical
models of glioma [30–34] and has warranted exploration
in ongoing clinical trials [35].
The current study suggests that the KD may shift the im-
munological landscape from inflammatory, non-protective
immune responses to cytotoxic Th1 responses and promo-
tion of immune mediated killing at the tumor site. Shifting
the balance toward a Th1 immune response leads to a gen-
eral change in cytokine milieu at the tumor site which alters
antigen presenting cell maturation and amount of overall
immune cell activation [36–41]. This may explain results
seen in this manuscript including increased NK and CD8+
T cell function, changes in CD4+ T cell recruitment, reduc-
tion in immune inhibitory receptor expression, and ligand
availability on the tumor cells themselves. It should be
noted that increased CD4 to CD8 T cell ratio may be indi-
cative of a Th2 type immune response at the tumor site
[42], which may promote an immune tolerance state; how-
ever, greater CD8 T cell activation in the tumors from mice
maintained on a KD suggests this is not the case.
It is known that activated T cells undergo metabolic
reprogramming in which glycolysis is required to sup-
port proliferation and efficient growth [43–46]. Recent
evidence also suggests that reduced glucose availability
and increased fatty acid oxidation favors T regulatory
cells over effector T cells [47]. However, tumor-
infiltrating T cells from mice fed the KD are still able to
mount effective responses, undergo appropriate differen-
tiation, and retain function even with the characteristic
drop in glucose availability that accompanies the KD. It
is currently unclear how the KD alters the metabolic ac-
tivity of lymphocytes and why this effect appears to be
specific to the lymphocytes isolated from the tumor
microenvironment. It is possible that T-cells can utilize
ketones as a primary energy source in place of glucose
in a way similar to that of normal cells in the brain
[48, 49]. Recent work has suggested that tumor cells may
outcompete other cells in the microenvironment for glu-
cose and other nutrients, thereby reducing the activation
of anti-tumor effector T cells [50, 51]. By providing ke-
tones as an alternative energy source for lymphocytes it
can be postulated that the KD may alleviate immunosup-
pression mediated by nutrient competition. Further stud-
ies are needed to explore this question and determine the
precise role of ketones in T cell metabolism.
While the effect of the KD on tumor-infiltrating lym-
phocytes has only recently been explored, existing pre-
clinical in vitro and in vivo data as well as case reports
and anecdotal information have generated increased
support for clinical testing. Prospective Phase I and II
clinical trials have been initiated to assess the safety, effi-
cacy and tolerability of the KD in patients with recurrent
GBM (ClinicalTrials.gov; NCT01754350; NCT01535911;
NCT01865162; NCT02149459). In addition, we have
initiated a phase I/II trial assessing the tolerability and
efficacy of the KD up-front, concurrently with radiation
and temozolomide in newly diagnosed GBM patients
(NCT02046187) based on our preclinical data demon-
strating that the KD, when given in combination with ra-
diation, dramatically enhances survival when compared
to radiation treatment alone [6]. The mechanisms
underlying this effect are still under investigation; how-
ever, as radiation-induced tumor killing is known to ex-
pose the immune system to a greater diversity of tumor
antigens, increased antigen processing, and increased
immunogenic cytotoxicity it is possible that the KD as
an adjuvant can work to augment the effect of radiation
in part by enhancing immunity against GBM.
Conclusions
In summary, the KD may work as an immune adjuvant
in the glioma microenvironment by reducing immune
suppression, and promoting Th1 type immune responses
against the tumor. These data provide additional support
for the use of the KD in combination with the current
standard of care and newer therapies for the treatment
of brain tumors.
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Additional files
Additional file 1: Figure S1. βHB, glucose and weight measurements.
Blood ketone and glucose measurements taken at days 7 and 14 post-
implantation show (A) higher βHB and (B) lower glucose in KD treated
animals (C) weight measurements were taken every 3–5 days. Graph
shows weights normalized to the average starting weight of each group.
N = 12 for immune competent mice; N = 5 for CD8 depleted mice;
student’s two-tailed t-test; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
(TIF 24634 kb)
Additional file 2: Figure S2. Confirmation of CD8 depletion in 2.43
treated mice. PBMCs were collected on day 7 post tumor inoculation
during CD8 depletion. PBMCs stained from mice fed KD versus SD,
analyzed using Flowjo 8.8.7. Percentage of CD8+ T cells in blood
indicated on plot. (TIF 3065 kb)
Additional file 3: Figure S3. Gating strategies for CD8+, CD4+, and
Treg T cells. Flow cytometry analysis was performed to assess the cell
types infiltrating tumors from mice fed both SD and KD. Percentage of
CD8 T cells (A), CD4 T cells (B) and CD4 + FoxP3+ T regulatory cells (C)
were assessed. (TIF 8002 kb)
Additional file 4: Figure S4. Gating strategies for inhibitory receptor
expression on CD8+ T cells. Flow cytometry analysis was performed to
assess the inhibitory receptor expression on tumor-infiltrating CD8+ T cells
from mice fed both SD and KD. Percentages of PD-1+ (A) and CTLA-4+ (B)
are indicated on flow plots. Data gating on CD8+ T cells. (TIF 6955 kb)
Additional file 5: Figure S5. Gating strategies for cytokine expression
of CD8+ T cells. Tumor-infiltrating lymphocytes (TILs) isolated from gliomas
from mice fed KD versus SD were cultured alone or in the presence of
GL261-Luc2 tumor cells. Analysis of IFNγ (A), TNF (B) and IL-2 (C) production
in tumor-infiltrating CD8+ T cells was performed. Percentage of positive cells
indicated on plots. (TIF 9343 kb)
Additional file 6: Figure S6. Gating strategies for cytokine expression
of T regulatory cells and NK cells. Tumor-infiltrating lymphocytes isolated
from gliomas from mice fed KD versus SD were cultured alone or in the
presence of GL261-Luc2 tumor cells. Analysis of IL-10 + Treg cells (A),
IFNγ + NK cells (B), and TNF + NK cells (C) was performed. Percentage of
positive cells indicated on plots. (TIF 10675 kb)
Abbreviations
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necrosis factor; IFNγ: interferon gamma; IL: interleukin.
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